Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (Q57955575)

From Wikidata

Jump to navigation Jump to search

scholarly article by Courtney Crim et al published January 2015 in Proceedings of the American Thoracic Society

Language	Label	Description	Also known as
English	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD	scholarly article by Courtney Crim et al published January 2015 in Proceedings of the American Thoracic Society

Statements

scholarly article

0 references

Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

object named as

Jørgen Vestbo

7

0 references

Nicola A Hanania

5

object named as

Nicola A. Hanania

0 references

Fernando J Martinez

9

object named as

Fernando J. Martinez

0 references

author name string

Courtney Crim

1

0 references

Mark T. Dransfield

2

0 references

Jean Bourbeau

3

0 references

Paul W. Jones

4

0 references

Donald A. Mahler

6

0 references

Andrew Wachtel

8

0 references

Frank Barnhart

10

0 references

Sally Lettis

11

0 references

Peter M. A. Calverley

12

0 references

publication date

January 2015

0 references

Proceedings of the American Thoracic Society

0 references

12

0 references

1

0 references

27-34

0 references

The burden of community-acquired pneumonia in seniors: results of a population-based study

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

The natural history of community-acquired pneumonia in COPD patients: a population database analysis.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Pneumonic vs nonpneumonic acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Risk factors for death and hospitalization from pneumonia. A prospective study of a general population

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Spirometric reference values from a sample of the general U.S. population

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Clinical practice. Community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Reported pneumonia in patients with COPD: findings from the INSPIRE study

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201409-413OC

21 January 2018

Identifiers

10.1513/ANNALSATS.201409-413OC

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57955575&oldid=1798686365"